Daxor Co. (NASDAQ:DXR) CEO Acquires $16,277.07 in Stock

Daxor Co. (NASDAQ:DXR) CEO Michael Richard Feldschuh purchased 2,063 shares of Daxor stock in a transaction dated Friday, April 4th. The stock was bought at an average cost of $7.89 per share, for a total transaction of $16,277.07. Following the completion of the purchase, the chief executive officer now directly owns 212,694 shares in the company, valued at approximately $1,678,155.66. This trade represents a 0.98 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Michael Richard Feldschuh also recently made the following trade(s):

• On Monday, March 10th, Michael Richard Feldschuh purchased 3,360 shares of Daxor stock. The stock was acquired at an average cost of $7.68 per share, with a total value of $25,804.80.

Daxor Trading Down 2.5 %

Daxor stock traded down $0.19 during midday trading on Monday, hitting $7.45. 3,899 shares of the company’s stock were exchanged, compared to its average volume of 7,245. Daxor Co. has a 12-month low of $6.55 and a 12-month high of $10.00. The firm’s 50 day simple moving average is $7.76 and its 200 day simple moving average is $8.38.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets increased their price objective on shares of Daxor from $24.75 to $25.00 and gave the company a “buy” rating in a research report on Monday, March 17th.

Institutional Investors Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Renaissance Technologies LLC boosted its holdings in shares of Daxor Co. (NASDAQ:DXR) by 87.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,821 shares of the company’s stock after acquiring an additional 13,000 shares during the period. Renaissance Technologies LLC owned about 0.57% of Daxor worth $214,000 at the end of the most recent reporting period. 1.34% of the stock is owned by institutional investors and hedge funds.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.